An FGFR1-Binding Peptide Modified Liposome for siRNA Delivery in Lung Cancer
Liposome modification by targeting ligands has been used to mediate specific interactions and drug delivery to target cells. In this study, a new peptide ligand, CP7, was found to be able to effectively bind to FGFR1 through reverse molecular docking and could cooperate with VEGFR3 to achieve target...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/15/8380 |
| _version_ | 1797441972281016320 |
|---|---|
| author | Zhipeng Dong Yunxue Yin Jun Luo Bingxia Li Fangning Lou Qiyan Wang Qingfa Zhou Baofen Ye Yue Wang |
| author_facet | Zhipeng Dong Yunxue Yin Jun Luo Bingxia Li Fangning Lou Qiyan Wang Qingfa Zhou Baofen Ye Yue Wang |
| author_sort | Zhipeng Dong |
| collection | DOAJ |
| description | Liposome modification by targeting ligands has been used to mediate specific interactions and drug delivery to target cells. In this study, a new peptide ligand, CP7, was found to be able to effectively bind to FGFR1 through reverse molecular docking and could cooperate with VEGFR3 to achieve targeting of A549 cells. CP7 was modified on the surface of the liposome to construct a targeted and safe nanovehicle for the delivery of a therapeutic gene, Mcl-1 siRNA. Due to the specific binding between CP7 and A549 cells, siRNA-loaded liposome-PEG-CP7 showed increased cellular uptake in vitro, resulting in significant apoptosis of tumor cells through silencing of the Mcl-1 gene, which is associated with apoptosis and angiogenesis. This gene delivery system also showed significantly better antitumor activity in tumor-bearing mice in vivo. All of these suggested that siRNA-loaded liposome-PEG-CP7 could be a promising gene drug delivery system with good bioavailability and minimal side effects for treatment. |
| first_indexed | 2024-03-09T12:34:00Z |
| format | Article |
| id | doaj.art-802861294996476081b0dc58273cf6c9 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T12:34:00Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-802861294996476081b0dc58273cf6c92023-11-30T22:26:29ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-07-012315838010.3390/ijms23158380An FGFR1-Binding Peptide Modified Liposome for siRNA Delivery in Lung CancerZhipeng Dong0Yunxue Yin1Jun Luo2Bingxia Li3Fangning Lou4Qiyan Wang5Qingfa Zhou6Baofen Ye7Yue Wang8Key Laboratory of Biomedical Functional Materials, School of Sciences, China Pharmaceutical University, Nanjing 211198, ChinaKey Laboratory of Biomedical Functional Materials, School of Sciences, China Pharmaceutical University, Nanjing 211198, ChinaKey Laboratory of Biomedical Functional Materials, School of Sciences, China Pharmaceutical University, Nanjing 211198, ChinaKey Laboratory of Biomedical Functional Materials, School of Sciences, China Pharmaceutical University, Nanjing 211198, ChinaKey Laboratory of Biomedical Functional Materials, School of Sciences, China Pharmaceutical University, Nanjing 211198, ChinaKey Laboratory of Biomedical Functional Materials, School of Sciences, China Pharmaceutical University, Nanjing 211198, ChinaKey Laboratory of Biomedical Functional Materials, School of Sciences, China Pharmaceutical University, Nanjing 211198, ChinaKey Laboratory of Biomedical Functional Materials, School of Sciences, China Pharmaceutical University, Nanjing 211198, ChinaKey Laboratory of Biomedical Functional Materials, School of Sciences, China Pharmaceutical University, Nanjing 211198, ChinaLiposome modification by targeting ligands has been used to mediate specific interactions and drug delivery to target cells. In this study, a new peptide ligand, CP7, was found to be able to effectively bind to FGFR1 through reverse molecular docking and could cooperate with VEGFR3 to achieve targeting of A549 cells. CP7 was modified on the surface of the liposome to construct a targeted and safe nanovehicle for the delivery of a therapeutic gene, Mcl-1 siRNA. Due to the specific binding between CP7 and A549 cells, siRNA-loaded liposome-PEG-CP7 showed increased cellular uptake in vitro, resulting in significant apoptosis of tumor cells through silencing of the Mcl-1 gene, which is associated with apoptosis and angiogenesis. This gene delivery system also showed significantly better antitumor activity in tumor-bearing mice in vivo. All of these suggested that siRNA-loaded liposome-PEG-CP7 could be a promising gene drug delivery system with good bioavailability and minimal side effects for treatment.https://www.mdpi.com/1422-0067/23/15/8380CP7liposometarget deliveryFGFR1gene drug |
| spellingShingle | Zhipeng Dong Yunxue Yin Jun Luo Bingxia Li Fangning Lou Qiyan Wang Qingfa Zhou Baofen Ye Yue Wang An FGFR1-Binding Peptide Modified Liposome for siRNA Delivery in Lung Cancer International Journal of Molecular Sciences CP7 liposome target delivery FGFR1 gene drug |
| title | An FGFR1-Binding Peptide Modified Liposome for siRNA Delivery in Lung Cancer |
| title_full | An FGFR1-Binding Peptide Modified Liposome for siRNA Delivery in Lung Cancer |
| title_fullStr | An FGFR1-Binding Peptide Modified Liposome for siRNA Delivery in Lung Cancer |
| title_full_unstemmed | An FGFR1-Binding Peptide Modified Liposome for siRNA Delivery in Lung Cancer |
| title_short | An FGFR1-Binding Peptide Modified Liposome for siRNA Delivery in Lung Cancer |
| title_sort | fgfr1 binding peptide modified liposome for sirna delivery in lung cancer |
| topic | CP7 liposome target delivery FGFR1 gene drug |
| url | https://www.mdpi.com/1422-0067/23/15/8380 |
| work_keys_str_mv | AT zhipengdong anfgfr1bindingpeptidemodifiedliposomeforsirnadeliveryinlungcancer AT yunxueyin anfgfr1bindingpeptidemodifiedliposomeforsirnadeliveryinlungcancer AT junluo anfgfr1bindingpeptidemodifiedliposomeforsirnadeliveryinlungcancer AT bingxiali anfgfr1bindingpeptidemodifiedliposomeforsirnadeliveryinlungcancer AT fangninglou anfgfr1bindingpeptidemodifiedliposomeforsirnadeliveryinlungcancer AT qiyanwang anfgfr1bindingpeptidemodifiedliposomeforsirnadeliveryinlungcancer AT qingfazhou anfgfr1bindingpeptidemodifiedliposomeforsirnadeliveryinlungcancer AT baofenye anfgfr1bindingpeptidemodifiedliposomeforsirnadeliveryinlungcancer AT yuewang anfgfr1bindingpeptidemodifiedliposomeforsirnadeliveryinlungcancer AT zhipengdong fgfr1bindingpeptidemodifiedliposomeforsirnadeliveryinlungcancer AT yunxueyin fgfr1bindingpeptidemodifiedliposomeforsirnadeliveryinlungcancer AT junluo fgfr1bindingpeptidemodifiedliposomeforsirnadeliveryinlungcancer AT bingxiali fgfr1bindingpeptidemodifiedliposomeforsirnadeliveryinlungcancer AT fangninglou fgfr1bindingpeptidemodifiedliposomeforsirnadeliveryinlungcancer AT qiyanwang fgfr1bindingpeptidemodifiedliposomeforsirnadeliveryinlungcancer AT qingfazhou fgfr1bindingpeptidemodifiedliposomeforsirnadeliveryinlungcancer AT baofenye fgfr1bindingpeptidemodifiedliposomeforsirnadeliveryinlungcancer AT yuewang fgfr1bindingpeptidemodifiedliposomeforsirnadeliveryinlungcancer |